Trial Profile
A phase III/IV open-label study of the immunogenicity and safety of a single dose of a Live Attenuated Influenza Vaccine (LAIV) (FluenzTM) for each of three successive years in children naïve to, or in previous receipt of the AS03B adjuvanted H1N1 (2009)
Status:
Completed
Phase of Trial:
Phase III/IV
Latest Information Update: 27 Feb 2020
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine live (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics; Proof of concept
- Acronyms LAIV Immuno
- 15 Feb 2020 Results evaluating the serum antibody (HAI) responses of children in our study cohort over successive years for influenza A and B, and also by NAI for A(H1N1)pdm09 published in the Vaccine
- 18 Apr 2018 Results assessing the immunogenicity of live attenuated influenza vaccine (LAIV) in children published in the Vaccine.
- 05 Apr 2017 Status changed from recruiting to completed.